Bone Metastasis (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis – Drugs In Development, 2021, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 7, 2, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 8, 1 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).

– The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Ablynx NV

Better Life Pharmaceuticals Inc

BiologicsMD Inc

BioNTech SE

Crescendo Biologics Ltd

CSPC Pharmaceutical Group Ltd

Eden Biologics Inc

Genor BioPharma Co Ltd

Hengenix Biotech Inc

Hualan Biological Engineering Inc

ITM Isotopen Technologien Munchen AG

Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Livzon Pharmaceutical Group Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

Mabwell Shanghai Bioscience Co Ltd

MetCure Therapeutics LLC

NeuClone Pty Ltd

Orion Biotechnology Canada Ltd

PEKKIP Oncology Alliance AG

Qilu Pharmaceutical Co Ltd

QSAM Therapeutics Inc

R-Pharm

Sandoz International GmbH

Serene LLC

Shanghai Biomabs Pharmaceuticals Co Ltd

Sonnet BioTherapeutics Holdings Inc

Terpenoid Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Bone Metastasis - Overview

Bone Metastasis - Therapeutics Development

Bone Metastasis - Therapeutics Assessment

Bone Metastasis - Companies Involved in Therapeutics Development

Bone Metastasis - Drug Profiles

Bone Metastasis - Dormant Projects

Bone Metastasis - Discontinued Products

Bone Metastasis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Bone Metastasis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Bone Metastasis – Pipeline by Ablynx NV, 2021

Bone Metastasis – Pipeline by Better Life Pharmaceuticals Inc, 2021

Bone Metastasis – Pipeline by BiologicsMD Inc, 2021

Bone Metastasis – Pipeline by BioNTech SE, 2021

Bone Metastasis – Pipeline by Crescendo Biologics Ltd, 2021

Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Ltd, 2021

Bone Metastasis – Pipeline by Eden Biologics Inc, 2021

Bone Metastasis – Pipeline by Genor BioPharma Co Ltd, 2021

Bone Metastasis – Pipeline by Hengenix Biotech Inc, 2021

Bone Metastasis – Pipeline by Hualan Biological Engineering Inc, 2021

Bone Metastasis – Pipeline by ITM Isotopen Technologien Munchen AG, 2021

Bone Metastasis – Pipeline by Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd, 2021

Bone Metastasis – Pipeline by Jiangsu T-mab BioPharma Co Ltd, 2021

Bone Metastasis – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2021

Bone Metastasis – Pipeline by Lupin Ltd, 2021

Bone Metastasis – Pipeline by Luye Pharma Group Ltd, 2021

Bone Metastasis – Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2021

Bone Metastasis – Pipeline by MetCure Therapeutics LLC, 2021

Bone Metastasis – Pipeline by NeuClone Pty Ltd, 2021

Bone Metastasis – Pipeline by Orion Biotechnology Canada Ltd, 2021

Bone Metastasis – Pipeline by PEKKIP Oncology Alliance AG, 2021

Bone Metastasis – Pipeline by Qilu Pharmaceutical Co Ltd, 2021

Bone Metastasis – Pipeline by QSAM Therapeutics Inc, 2021

Bone Metastasis – Pipeline by R-Pharm, 2021

Bone Metastasis – Pipeline by Sandoz International GmbH, 2021

Bone Metastasis – Pipeline by Serene LLC, 2021

Bone Metastasis – Pipeline by Shanghai Biomabs Pharmaceuticals Co Ltd, 2021

Bone Metastasis – Pipeline by Sonnet BioTherapeutics Holdings Inc, 2021

Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc, 2021

Bone Metastasis – Dormant Projects, 2021

Bone Metastasis – Dormant Projects, 2021 (Contd..1)

Bone Metastasis – Dormant Projects, 2021 (Contd..2)

Bone Metastasis – Dormant Projects, 2021 (Contd..3)

Bone Metastasis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Bone Metastasis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports